Orbus’s combo misses primary endpoint in Phase III brain cancer trial

Orbus Therapeutics’ lead therapy eflornithine has failed to achieve the primary endpoint in the Phase III STELLAR trial, evaluating it as a combination treatment with chemotherapy, lomustine, in patients with recurrent isocitrate dehydrogenase (IDH) mutant astrocytoma.